Patents Examined by Kristin Vajda
  • Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
    Patent number: 11098010
    Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 24, 2021
    Assignee: Arbutus Biopharma Corporation
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Ramesh Kakarla, Steven Kultgen, Jorge Quintero
  • Organic electroluminescent materials and devices
    Patent number: 11098245
    Abstract: Novel Iridium complexes having three different bidentate ligands useful for phosphorescent emitters in OLEDs are disclosed. At least one of the three different bidentate ligands is a carbene ligand.
    Type: Grant
    Filed: September 7, 2019
    Date of Patent: August 24, 2021
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Jui-Yi Tsai, Chuanjun Xia, Chun Lin, Adrian U. Palacios, Enrique Oñate, Miguel A. Esteruelas, Pierre-Luc T. Boudreault, Sonia Bajo, Montserrat Oliván
  • Adducts of pyrrole derivatives to carbon allotropes
    Patent number: 11098012
    Abstract: Adducts are described formed between pyrrole derivatives of formula (I) an carbon allotropes in which the carbon is sp2 hybridized, such as for example carbon nanotubes, graphene or nanographites, carbon black. The pyrrole derivatives bear substituents on the nitrogen atom suitable for improving the physicochemical characteristics of said allotropes. A process for preparing said adducts is also described. The adducts are formed with a pyrrole of formula (I) wherein X is selected from the group consisting of: The other substituents are as defined in the claims.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: August 24, 2021
    Assignee: PIRELLI TYRE S.p.A.
    Inventors: Maurizio Stefano Galimberti, Vincenzina Barbera
  • Therapeutic heterocyclic compounds
    Patent number: 11098027
    Abstract: Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 24, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Elfatih Elzein, Xiaofen Li
  • Composition for preventing or treating muscle diseases, comprising suberic acid or pharmaceutically acceptable salt thereof as active ingredient
    Patent number: 11096917
    Abstract: The present invention relates to a composition for preventing or treating a muscular disease or improving muscle function. The composition includes suberic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 24, 2021
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventor: Tae Sun Park
  • Aminophosphinic derivatives for preventing and treating eye inflammation
    Patent number: 11090317
    Abstract: The disclosure relates to compounds of formula (I): R1-NH—CH(R2)-P(?O)(OH)—CH2-C(R3)(R4)-CONH—C(R5)(R6)-COOR7, where R1 to R7 are as defined in the claims, for use of same in the treatment and/or prevention of ocular inflammation, and more particularly for improving the process of ocular healing. Thus, the compounds of formula (I) are used, in particular, to prevent neovascularisation, or to prevent or treat an ocular inflammation linked to a keratitis, scleritis, episcleritis, uveitis, cataract, synechia, macular oedema, detachment of the retina, ocular hypertension and degeneration of the optical nerve caused by glaucoma.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: August 17, 2021
    Assignee: Pharmaleads
    Inventors: Hervé Poras, Michel Wurm, Stéphane Melik Parsadaniantz, Annabelle Reaux-Le Goazigo
  • Compounds and compositions for inducing chondrogenesis
    Patent number: 11091499
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: August 17, 2021
    Assignee: Novartis AG
    Inventors: Ha-Soon Choi, Jiqing Jiang, James Paul Lajiness, Bao Nguyen, Hank Michael James Petrassi
  • Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
    Patent number: 11084800
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: August 10, 2021
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, Joel Charles Barrish, William Greenlee, Kyle J. Eastman
  • Compositions of cyclin dependent kinase 7 (CDK7) inhibitor
    Patent number: 11083728
    Abstract: The present invention provides, in part, compositions comprising an inhibitor of cyclin-dependent kinase 7 (CDK7) and sulfobutyl ether-?-cyclodextrin. Also provided are methods of using a disclosed composition for treating proliferative diseases. The present invention also provides methods of making disclosed compositions.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: August 10, 2021
    Assignee: Syros Pharmaceuticals, Inc.
    Inventor: Neera Jain
  • Pharmaceutical compounds
    Patent number: 11078189
    Abstract: Benzimidazole derivatives of formula (I): wherein: R1 is —(CH2)m-R4 or R2 is halo, —(CH2)m—NH2 or —(CH2)n—C(?NH)—NH2; R3 is H or F; R4 is —NH—(CH2)2—(NH)r—R5, —NH—(CHR5R6) or a group of the following formula (A): (A) W is —(CH2)m—, —CH2—O—CH2—, —CH2—S—CH2—, —(CH2)r—S(O)2—CH2— or —(CH2)r—NR5—CH2—; m is an integer of 1 to 3; n is 1 or 2; p is 1 and V is CH; or p is O and V is N; q is 0 or 1; r is 0 or 1; R5 is H, —SO2Me, —SO2Et, —SO2CF3, —COMe, —CONMe2, —CONH2 or —CH2CH2SO2Me; R6 is H or C1-C6 alkyl; and R7 is —SO2Me, —SO2Et, —SO2CF3, —COMe, —CONMe2, —CONH2 or —CH2CH2SO2Me; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: August 3, 2021
    Assignee: REVIRAL LIMITED
    Inventors: Stuart George Cockerill, James Good
  • Therapy for mitochondrial fatty acid beta-oxidation and transport disorders
    Patent number: 11077105
    Abstract: Methods of treating mitochondrial fatty acid b-oxidation and/or transport disorders arising from mutant proteins in the mitochondrial fatty acid ?-oxidation and transport metabolic pathways in patients are provided. The methods modulate the mitochondrial fatty acid ?-oxidation pathway at the last step so that the product of the mutant protein accumulates and stabilizes the mutant protein and/or the substrate(s)/product(s) of the down stream reactions accumulate and possibly bind to allosteric sites on the mutant protein to stabilize it. Trimetazidine pharmacodynamics function as such in the ?-oxidation pathway. Further, a synergistic effect is observed where trimetazidine and PPAR? agonist combination enhanced enzyme activity and presence significantly more than either alone.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: August 3, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Al-Walid A. Mohsen, Gerard Vockley
  • Opioid receptor ligands and methods of using and making same
    Patent number: 11077098
    Abstract: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: August 3, 2021
    Assignee: Trevena, Inc.
    Inventors: Dennis Yamashita, Dimitar Gotchev, Philip Pitis, Xiao-Tao Chen, Guodong Liu, Catherine C. K. Yuan
  • 5-membered and bicyclic heterocyclic amides as inhibitors of rock
    Patent number: 11078197
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: August 3, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
  • Tetrazole compounds and their use in the treatment of tuberculosis
    Patent number: 11072591
    Abstract: The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by Mycobacterium, such as tuberculosis.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: July 27, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Carlos Alemparte-Gallardo, Lourdes Encinas, Jorge Esquivias Provencio
  • Gracilin A and congeners as immunosuppressive and neuroprotective agents
    Patent number: 11066379
    Abstract: Gracilin A congeners and methods for their use as immunosuppressive and neuroprotective agents.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: July 20, 2021
    Assignees: The Texas A&M University System, Universidade de Santiago de Compostela
    Inventors: Daniel Romo, Mikail E. Abbasov, Eva Alonso Lopez, Maria Amparo Alfonso Rancano, Miguel Luis Botana Lopez
  • Substituted pyrrolidine compound and use thereof
    Patent number: 11059780
    Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: July 13, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masaki Daini, Yuhei Miyanohana, Satoshi Mikami, Yuichi Kajita, Masaki Ogino, Tatsuki Koike, Kohei Takeuchi
  • Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist
    Patent number: 11052065
    Abstract: The present invention relates to methods of treating a cell proliferation disorder (e.g., cancer) comprising administering: (a) a compound having the Formula (I), wherein R1 or R2 are as herein defined, or a pharmaceutically acceptable salt thereof; and (b) an anti-human PD-1 antibody or antigen binding fragment thereof to a human patient in need thereof. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: July 6, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Elaine M Pinheiro, Michael Rosenzweig, Robert A. Kastelein, David R. Kaufman, Deborah A. Law
  • Dimethylphosphine oxide compound
    Patent number: 11046720
    Abstract: Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: June 29, 2021
    Assignee: GUIZHOU INOCHINI TECHNOLOGY CO., LTD
    Inventors: Lingyun Wu, XiaWei Wei, Peng Zhang, Zhaoguo Chen, Cailin Wang, Lele Zhao, Jian Li, Shuhui Chen
  • Small molecule antimicrobials
    Patent number: 11046668
    Abstract: Compounds and compositions of matter are provided that are small molecule antimicrobials. The compounds are selected from JH-144, TH-04 or TH-08 or combinations thereof. Compositions of matter are provided which in an embodiment may comprise a carrier, and in further embodiments may comprise a pharmaceutically acceptable excipient, film, biofilm or edible film. Methods of use are provided in which the composition may be administered to a subject in need thereof, and in an embodiment where the subject has a bacterial infection. Other embodiments provide the composition may be contacted with surface to eliminate or reduce bacteria.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: June 29, 2021
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Gireesh Rajashekara, Ulyana Munoz Acuna, Janet Antwi, Esperanza Carcache de Blanco, James Fuchs, Anand Kumar, Corey Nislow, Melvin Pascall, Zilu Wan
  • Heteroaryl-substituted triazoles as APJ receptor agonists
    Patent number: 11046680
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 29, 2021
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Frank Kayser, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Kevin Yang, Wen-Chen Yeh